| Control (no resveratrol) | 5 mg Resveratrol | 1 g Resveratrol | |
|---|---|---|---|
| Number of patients | 11 recruited 9 completed 2 incompletea |
10 recruited 8 completed 2 incompleteb |
10 recruited 7 completed 2 incompleteb,c 1 collected as controld |
| Age (years) mean ± SD (range) | 66.3 ± 10.9 (44–80) | 72.7 ± 12.3 (45–88) | 69.1 ± 11.5 (43–85) |
| Gender | 5 male, 6 female | 8 male, 2 female | 8 male, 2 female |
| Previous chemoradiotherapy | 4 | 0 | 1 |
a
Two patients in the control group did not complete the study as their operations were cancelled due to brain metastases and viscus perforation.
b
Three patients, two from the 5 mg dose group and one from the 1 g dose group did not complete the study as their tumours were found to be inoperable at laparotomy.
c
One patient received their completed the resveratrol course, including the [14C]-labelled dose but their surgery was then postponed for 6 days. Tissue was taken during the rescheduled surgery and is included, as appropriate in the analysis (Supplementary Table 2B).
d
One patient in the 1 g group was operated on before commencing resveratrol capsules, due to a cancellation slot becoming available. Tissue was collected as a control sample.